$752 Million is the total value of Cormorant Asset Management, LP's 80 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 32.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALKS | ALKERMES PLC | $45,038,000 | +5.5% | 700,000 | 0.0% | 5.99% | -9.2% | |
| HRTX | Buy | HERON THERAPEUTICS INC | $44,870,000 | +142.8% | 1,440,000 | +13.4% | 5.97% | +108.9% |
| RCPT | Sell | RECEPTOS INC | $41,811,000 | -35.0% | 220,000 | -43.6% | 5.56% | -44.1% |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $40,123,000 | +337.9% | 757,475 | +138.6% | 5.33% | +276.7% |
| DYAX | Buy | DYAX CORP | $37,100,000 | +94.4% | 1,400,000 | +22.9% | 4.93% | +67.3% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $34,335,000 | +20.3% | 718,900 | 0.0% | 4.56% | +3.5% | |
| SRNE | Buy | SORRENTO THERAPEUTICS INC | $34,277,000 | +79.4% | 1,945,334 | +17.7% | 4.56% | +54.3% |
| EGRX | Sell | EAGLE PHARMACEUTICALS INC | $24,258,000 | -19.2% | 300,000 | -58.1% | 3.22% | -30.5% |
| ARDX | Buy | ARDELYX INC | $23,653,000 | +78.2% | 1,481,075 | +46.1% | 3.14% | +53.3% |
| PTLA | Sell | PORTOLA PHARMACEUTICALS INC | $22,775,000 | +4.4% | 500,000 | -13.0% | 3.03% | -10.1% |
| NVAX | Buy | NOVAVAX INC | $17,824,000 | +74.0% | 1,600,000 | +29.2% | 2.37% | +49.7% |
| TSRO | Buy | TESARO INC | $17,123,000 | +56.0% | 291,250 | +52.3% | 2.28% | +34.3% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $16,782,000 | – | 140,000 | +100.0% | 2.23% | – |
| QTNT | QUOTIENT LTD | $16,551,000 | -13.0% | 1,119,100 | 0.0% | 2.20% | -25.2% | |
| CHRS | Buy | COHERUS BIOSCIENCES INC | $16,448,000 | +145.5% | 569,130 | +159.7% | 2.19% | +111.1% |
| ADXS | Sell | ADVAXIS INC | $16,264,000 | +15.5% | 800,000 | -18.0% | 2.16% | -0.6% |
| AGEN | Buy | AGENUS INC | $13,454,000 | +86.1% | 1,559,000 | +10.6% | 1.79% | +60.2% |
| CBPO | Buy | CHINA BIOLOGIC PRODS INC | $12,840,000 | +75.7% | 111,500 | +45.8% | 1.71% | +51.2% |
| DXCM | DEXCOM INC | $12,237,000 | +28.3% | 153,000 | 0.0% | 1.63% | +10.4% | |
| PFNX | Buy | PFENEX INC | $12,123,000 | +60.1% | 624,900 | +31.6% | 1.61% | +37.8% |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $11,713,000 | – | 500,000 | +100.0% | 1.56% | – |
| NVRO | Buy | NEVRO CORP | $11,207,000 | +2653.6% | 208,500 | +2352.9% | 1.49% | +2265.1% |
| RARE | ULTRAGENYX PHARMACEUTICAL IN | $10,444,000 | +64.9% | 102,000 | 0.0% | 1.39% | +41.9% | |
| BCRX | BIOCRYST PHARMACEUTICALS | $10,152,000 | +65.3% | 680,000 | 0.0% | 1.35% | +42.3% | |
| REPH | Buy | RECRO PHARMA INC | $10,078,000 | +69.4% | 780,000 | +18.9% | 1.34% | +45.8% |
| RGLS | REGULUS THERAPEUTICS INC | $9,826,000 | -35.3% | 896,522 | 0.0% | 1.31% | -44.4% | |
| FWP | FORWARD PHARMA A/Ssponsored adr | $9,703,000 | +34.4% | 255,000 | 0.0% | 1.29% | +15.6% | |
| CRIS | CURIS INC | $8,712,000 | +37.9% | 2,632,000 | 0.0% | 1.16% | +18.6% | |
| KERX | KERYX BIOPHARMACEUTICALS INC | $8,243,000 | -21.6% | 826,000 | 0.0% | 1.10% | -32.6% | |
| KPTI | KARYOPHARM THERAPEUTICS INC | $8,190,000 | -11.1% | 300,987 | 0.0% | 1.09% | -23.5% | |
| COLL | New | COLLEGIUM PHARMACEUTICAL INC | $8,028,000 | – | 450,000 | +100.0% | 1.07% | – |
| OVAS | Sell | OVASCIENCE INC | $7,296,000 | -54.6% | 252,180 | -45.5% | 0.97% | -60.9% |
| OMER | OMEROS CORP | $6,989,000 | -18.3% | 388,500 | 0.0% | 0.93% | -29.8% | |
| NERV | Buy | MINERVA NEUROSCIENCES INC | $6,641,000 | +16.0% | 1,145,053 | +0.0% | 0.88% | -0.2% |
| EPZM | EPIZYME INC | $6,390,000 | +27.8% | 266,250 | 0.0% | 0.85% | +10.0% | |
| XLRN | Buy | ACCELERON PHARMA INC | $6,328,000 | -2.2% | 200,000 | +17.6% | 0.84% | -15.9% |
| ARRY | ARRAY BIOPHARMA INC | $6,129,000 | -2.2% | 850,000 | 0.0% | 0.82% | -15.8% | |
| LPCN | LIPOCINE INC NEW | $5,720,000 | +24.3% | 666,666 | 0.0% | 0.76% | +6.9% | |
| APTOSE BIOSCIENCES INC | $5,542,000 | -4.9% | 1,081,867 | 0.0% | 0.74% | -18.1% | ||
| RMTI | ROCKWELL MEDICAL INC | $5,481,000 | +47.5% | 340,000 | 0.0% | 0.73% | +27.0% | |
| EPRSQ | EPIRUS BIOPHARMACEUTICALS IN | $5,120,000 | -36.2% | 896,600 | 0.0% | 0.68% | -45.1% | |
| NKTR | NEKTAR THERAPEUTICS | $4,973,000 | +13.7% | 397,500 | 0.0% | 0.66% | -2.2% | |
| LBIO | Buy | LION BIOTECHNOLOGIES INC | $4,583,000 | -10.9% | 499,815 | +17.7% | 0.61% | -23.4% |
| KITE | Sell | KITE PHARMA INC | $4,195,000 | -27.3% | 68,800 | -31.2% | 0.56% | -37.4% |
| SGMO | Sell | SANGAMO BIOSCIENCES INC | $4,003,000 | -42.2% | 361,000 | -18.3% | 0.53% | -50.3% |
| IMDZ | Buy | IMMUNE DESIGN CORP | $3,903,000 | +55.4% | 189,000 | +58.8% | 0.52% | +33.8% |
| CYAD | New | CELYAD SAadr | $3,902,000 | – | 75,000 | +100.0% | 0.52% | – |
| GLYC | GLYCOMIMETICS INC | $3,649,000 | -4.5% | 458,955 | 0.0% | 0.48% | -17.8% | |
| ACRX | ACELRX PHARMACEUTICALS INC | $3,604,000 | +9.8% | 850,000 | 0.0% | 0.48% | -5.5% | |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $3,418,000 | -16.3% | 245,000 | +44.1% | 0.45% | -28.1% |
| DERM | DERMIRA INC | $2,984,000 | +14.3% | 170,000 | 0.0% | 0.40% | -1.5% | |
| New | TETRALOGIC PHARMACEUTICAL Cnote 8.000% 6/1 | $2,978,000 | – | 5,000,000 | +100.0% | 0.40% | – | |
| FOLD | New | AMICUS THERAPEUTICS INC | $2,830,000 | – | 200,000 | +100.0% | 0.38% | – |
| AVEO | New | AVEO PHARMACEUTICALS INC | $2,763,000 | – | 1,587,715 | +100.0% | 0.37% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $2,649,000 | – | 100,000 | +100.0% | 0.35% | – |
| ATRA | New | ATARA BIOTHERAPEUTICS INC | $2,638,000 | – | 50,000 | +100.0% | 0.35% | – |
| VSAR | VERSARTIS INC | $2,587,000 | -17.2% | 170,000 | 0.0% | 0.34% | -28.8% | |
| CERU | Buy | CERULEAN PHARMA INC | $2,536,000 | -29.9% | 551,354 | +37.4% | 0.34% | -39.7% |
| GNVC | Sell | GENVEC INC | $2,400,000 | -35.6% | 1,176,235 | -6.9% | 0.32% | -44.6% |
| HTGM | New | HTG MOLECULAR DIAGNOSTICS IN | $2,241,000 | – | 201,000 | +100.0% | 0.30% | – |
| KIN | KINDRED BIOSCIENCES INC | $2,240,000 | -4.5% | 328,497 | 0.0% | 0.30% | -17.7% | |
| MCRB | New | SERES THERAPEUTICS INC | $2,075,000 | – | 50,000 | +100.0% | 0.28% | – |
| AQXP | AQUINOX PHARMACEUTICALS INC | $1,943,000 | -15.6% | 279,900 | 0.0% | 0.26% | -27.5% | |
| AGRX | AGILE THERAPEUTICS INC | $1,564,000 | -7.3% | 182,053 | 0.0% | 0.21% | -20.3% | |
| VCYT | Buy | VERACYTE INC | $1,537,000 | +56.2% | 137,990 | +2.1% | 0.20% | +34.2% |
| CLRB | CELLECTAR BIOSCIENCES INC | $1,526,000 | -7.4% | 530,000 | 0.0% | 0.20% | -20.4% | |
| NSTG | Sell | NANOSTRING TECHNOLOGIES INC | $1,234,000 | -56.0% | 80,000 | -70.9% | 0.16% | -62.1% |
| CFRX | New | CONTRAFECT CORP | $1,231,000 | – | 234,406 | +100.0% | 0.16% | – |
| PVCT | New | PROVECTUS BIOPHARMACEUTICALS | $1,188,000 | – | 2,200,000 | +100.0% | 0.16% | – |
| ASND | ASCENDIS PHARMA A Sspnsored adr | $1,087,000 | +1.9% | 61,500 | 0.0% | 0.14% | -12.1% | |
| AKBA | AKEBIA THERAPEUTICS INC | $1,032,000 | -7.4% | 100,300 | 0.0% | 0.14% | -20.3% | |
| BITI | New | BIOTIE THERAPIES OYJsponsored adr | $999,000 | – | 50,000 | +100.0% | 0.13% | – |
| SCYX | SCYNEXIS INC | $873,000 | +5.8% | 99,366 | 0.0% | 0.12% | -8.7% | |
| GALT | GALECTIN THERAPEUTICS INC | $781,000 | -18.6% | 286,200 | 0.0% | 0.10% | -29.7% | |
| PVCTW | New | PROVECTUS BIOPHARMACEUTICALS*w exp 06/24/202 | $480,000 | – | 2,200,000 | +100.0% | 0.06% | – |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $458,000 | – | 25,000 | +100.0% | 0.06% | – |
| CLRBW | CELLECTAR BIOSCIENCES INC*w exp 08/19/201 | $413,000 | 0.0% | 530,000 | 0.0% | 0.06% | -14.1% | |
| CLLS | Sell | CELLECTIS S Asponsored ads | $408,000 | -52.8% | 11,300 | -54.8% | 0.05% | -59.7% |
| AGTC | Sell | APPLIED GENETIC TECHNOL CORP | $262,000 | -49.6% | 17,110 | -34.2% | 0.04% | -56.2% |
| CLTX | CELSUS THERAPEUTICS PLCsponsored adr ne | $166,000 | -23.9% | 286,508 | 0.0% | 0.02% | -35.3% | |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -850 | -100.0% | -0.01% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -8,500 | -100.0% | -0.08% | – |
| BLCM | Exit | BELLICUM PHARMACEUTICALS INC | $0 | – | -51,000 | -100.0% | -0.18% | – |
| GEVA | Exit | SYNAGEVA BIOPHARMA CORP | $0 | – | -42,500 | -100.0% | -0.64% | – |
| CMRX | Exit | CHIMERIX INC | $0 | – | -229,500 | -100.0% | -1.34% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB CO | $0 | – | -459,000 | -100.0% | -4.58% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -167,300 | -100.0% | -6.10% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.